Sagent Pharmaceuticals Introduces Zyogreen®: A Game Changer in Fluorescence Imaging Procedures

Sagent Pharmaceuticals Launches Zyogreen®

SCHAUMBURG, Ill., September 22, 2026 – The healthcare landscape is evolving, and Sagent Pharmaceuticals is at the forefront with the launch of Zyogreen®, marking a significant milestone in surgical imaging technology. This innovative product is the first and only ready-to-use (RTU) indocyanine green (ICG) injection approved by the FDA, designed to enhance fluorescence-guided surgical procedures.

A Revolutionary Product

Zyogreen offers a significant advantage over conventional ICG products, which typically come as a lyophilized powder requiring reconstitution before use. With Zyogreen, healthcare providers can utilize a sterile solution ready for immediate application, essentially streamlining workflows in surgical and imaging departments. This is particularly beneficial in vascular, gastrointestinal, organ transplant, plastic, reconstructive surgeries, and various diagnostic imaging procedures.

As the U.S. market for indocyanine green approaches $128 million as of July 2026, Sagent has positioned Zyogreen not merely as an operational alternative but as a transformative agent within the healthcare industry. Surgeons across multiple disciplines, including gynecologic oncology and ophthalmology, will benefit from enhanced visualization capabilities that Zyogreen provides.

Statement from Leadership

Vishy Chebrol, CEO of Sagent Pharmaceuticals, stated, “This launch is a crucial part of our growth as a company focused on specialty pharmaceuticals. Zyogreen combines the clinical benefits of indocyanine green with the convenience of a ready-to-use formulation, giving surgical teams a trustworthy options in their practices.” He further emphasized the firm’s commitment to ensuring a reliable supply chain in collaboration with Provepharm, a leader in medical dyes contributing to the development of Zyogreen.

Enhanced Patient Care

Zyogreen isn’t just a technical advancement; it is designed with the patient’s safety and healthcare outcomes in mind. Not only is its formulation pivotal for quick administrative use, but it is also a versatile agent, indicated for different applications such as fluorescence imaging of vessels and blood flow, lymphatic mapping in certain cancers, and more. The product is suitable for both adult and pediatric use, making it a critical tool in various settings.

In the footsteps of its previous product, Bludigo®—the first FDA-approved injectable indigo carmine diagnostic dye—Sagent’s introduction of Zyogreen continues to establish its growing impact on surgical visualization and diagnostics.

Safety Information

As with any medical product, understanding potential risks is vital. Zyogreen is contraindicated in patients with a history of hypersensitivity to indocyanine green, with adverse reactions possibly including anaphylaxis. As such, healthcare personnel are advised to be vigilant and prepared for any hypersensitivity reactions during administration. Detailed prescribing information outlines these critical safety parameters comprehensively.

Conclusion

With Zyogreen now available through its extensive distribution networks, Sagent Pharmaceuticals is ensuring that cutting-edge solutions reach the healthcare professionals who rely on accurate imaging techniques. This launch reinforces the company’s position not just as a pharmaceutical provider but as an innovator committed to improving healthcare outcomes through smart, practical solutions.

For further information on Zyogreen and its applications, or to explore Sagent’s commitment to healthcare excellence, visit Sagent Pharmaceuticals.